The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results